Morgan Stanley
TVRD

Morgan Stanley’s Tvardi Therapeutics TVRD Stock Holding History

Morgan Stanley’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Sell
72,894
-11,572
-14% -$45.3K ﹤0.01% 5813
2025
Q4 		$363K Buy
84,466
+80,680
+2,131% +$723K ﹤0.01% 5676
2025
Q3 		$148K Sell
3,786
-1,108
-23% -$31.5K ﹤0.01% 6004
2025
Q2 		$114K Buy
4,894
+4,523
+1,219% +$107K ﹤0.01% 6084
2025
Q1 		$5.65K Sell
371
-63
-15% -$951 ﹤0.01% 6958
2024
Q4 		$7.97K Sell
434
-15
-3% -$163 ﹤0.01% 6879
2024
Q3 		$4.98K Sell
449
-1,476
-77% -$17.3K ﹤0.01% 6919
2024
Q2 		$17.9K Sell
1,925
-1,016
-35% -$24.2K ﹤0.01% 6504
2024
Q1 		$96.3K Sell
2,941
-13,345
-82% -$346K ﹤0.01% 6006
2023
Q4 		$436K Buy
16,286
+7,368
+83% +$305K ﹤0.01% 5672
2023
Q3 		$539K Buy
8,918
+156
+2% +$14.6K ﹤0.01% 5135
2023
Q2 		$893K Sell
8,762
-1,794
-17% -$247K ﹤0.01% 4898
2023
Q1 		$1.87M Sell
10,556
-3,161
-23% -$1.06M ﹤0.01% 4501
2022
Q4 		$5.3M Buy
13,717
+1,774
+15% +$674K ﹤0.01% 3712
2022
Q3 		$4.02M Buy
11,943
+3,925
+49% +$1.42M ﹤0.01% 3873
2022
Q2 		$2.63M Buy
8,018
+1,288
+19% +$452K ﹤0.01% 4321
2022
Q1 		$2.94M Buy
6,730
+377
+6% +$155K ﹤0.01% 4214
2021
Q4 		$2.79M Sell
6,353
-2,640
-29% -$1.33M ﹤0.01% 4298
2021
Q3 		$5M Sell
8,993
-3,105
-26% -$1.56M ﹤0.01% 3708
2021
Q2 		$6.21M Buy
12,098
+5,621
+87% +$3.56M ﹤0.01% 3552
2021
Q1 		$5.06M Buy
6,477
+2,830
+78% +$1.94M ﹤0.01% 3396
2020
Q4 		$1.99M Buy
3,647
+2,327
+176% +$1.22M ﹤0.01% 4167
2020
Q3 		$605K Sell
1,320
-110
-8% -$63.9K ﹤0.01% 4546
2020
Q2 		$881K Sell
1,430
-711
-33% -$393K ﹤0.01% 4267
2020
Q1 		$1.02M Buy
2,141
+148
+7% +$80.4K ﹤0.01% 3936
2019
Q4 		$1.16M Buy
1,993
+979
+97% +$687K ﹤0.01% 4443
2019
Q3 		$667K Buy
1,014
+429
+73% +$357K ﹤0.01% 4537
2019
Q2 		$453K Sell
585
-294
-33% -$207K ﹤0.01% 4652
2019
Q1 		$621K Sell
879
-4,411
-83% -$2.64M ﹤0.01% 4429
2018
Q4 		$2.48M Buy
5,290
+3,031
+134% +$1.96M ﹤0.01% 3584
2018
Q3 		$1.95M Buy
2,259
+134
+6% +$96.7K ﹤0.01% 4022
2018
Q2 		$1.47M Buy
2,125
+16
+0.8% +$8.13K ﹤0.01% 4342
2018
Q1 		$939K Sell
2,109
-4,044
-66% -$1.96M ﹤0.01% 4583
2017
Q4 		$2.71M Buy
6,153
+1,151
+23% +$525K ﹤0.01% 3748
2017
Q3 		$2.46M Sell
5,002
-9,651
-66% -$4.83M ﹤0.01% 3671
2017
Q2 		$8.12M Buy
14,653
+5,414
+59% +$3.44M ﹤0.01% 2377
2017
Q1 		$6.12M Buy
9,239
+7,232
+360% +$3.86M ﹤0.01% 2657
2016
Q4 		$671K Sell
2,007
-2,794
-58% -$897K ﹤0.01% 4741
2016
Q3 		$1.44M Buy
4,801
+3,614
+304% +$783K ﹤0.01% 3757
2016
Q2 		$206K Buy
1,187
+751
+172% +$164K ﹤0.01% 4922
2016
Q1 		$98K Sell
436
-177
-29% -$52.9K ﹤0.01% 5329
2015
Q4 		$373K Sell
613
-419
-41% -$230K ﹤0.01% 4737
2015
Q3 		$531K Buy
1,032
+632
+158% +$423K ﹤0.01% 4568
2015
Q2 		$176K Sell
400
-17
-4% -$6.57K ﹤0.01% 5307
2015
Q1 		$151K Buy
417
+411
+6,850% +$156K ﹤0.01% 5338
2014
Q4 		$2K Sell
6
-136
-96% -$43.8K ﹤0.01% 6443
2014
Q3 		$43K Sell
142
-30
-17% -$12.3K ﹤0.01% 5782
2014
Q2 		$106K Sell
172
-1,200
-87% -$646K ﹤0.01% 5473
2014
Q1 		$920K Buy
+1,372
New +$812K ﹤0.01% 4061

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley's TVRD Position: Q1 2026 in Review

Morgan Stanley reduced its Tvardi Therapeutics (TVRD) stake by 14% in Q1 2026, selling an estimated $45.3K and leaving 72,894 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #5813.

Morgan Stanley first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.12M in Q2 2017. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Morgan Stanley held 72,894 shares of Tvardi Therapeutics worth $232K as of Q1 2026.
  • Morgan Stanley sold 11,572 Tvardi Therapeutics shares in Q1 2026, an estimated $45.3K.
  • Tvardi Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5813 holding.
  • Morgan Stanley first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Morgan Stanley's Tvardi Therapeutics position peaked at $8.12M in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.